Equity Overview
Price & Market Data
Price: $32.34
Daily Change: -$0.08 / 0.25%
Daily Range: $31.15 - $32.96
Market Cap: $1,565,554,560
Daily Volume: 393,634
Performance Metrics
1 Week: -0.92%
1 Month: -6.15%
3 Months: 17.81%
6 Months: 124.6%
1 Year: 186.7%
YTD: 6.70%
Company Details
Employees: 28
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.